164 related articles for article (PubMed ID: 16222150)
1. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231.
Bigioni M; Benzo A; Irrissuto C; Maggi CA; Goso C
Anticancer Drugs; 2005 Nov; 16(10):1083-9. PubMed ID: 16222150
[TBL] [Abstract][Full Text] [Related]
2. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
Tauer U; Zhao Y; Hunt SP; Culman J
Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
4. Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs.
Ricciardolo FL; Trevisani M; Geppetti P; Nadel JA; Amadesi S; Bertrand C
Br J Pharmacol; 2000 Mar; 129(5):915-20. PubMed ID: 10696090
[TBL] [Abstract][Full Text] [Related]
5. Effects of selective tachykinin-receptor antagonists on tachykinin-induced airway mucus secretion in the rat.
Wagner U; Fehmann H; Bredenbröker D; Klüber D; Lange A; Wichert P
Neuropeptides; 1999 Feb; 33(1):55-61. PubMed ID: 10657472
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
Picard P; Regoli D; Couture R
Br J Pharmacol; 1994 May; 112(1):240-9. PubMed ID: 7518304
[TBL] [Abstract][Full Text] [Related]
7. Tachykinin effects on bladder activity in conscious normal rats.
Ishizuka O; Mattiasson A; Andersson KE
J Urol; 1995 Jul; 154(1):257-61. PubMed ID: 7539864
[TBL] [Abstract][Full Text] [Related]
8. Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M; Boczek-Leszczyk E
J Physiol Pharmacol; 2008 Sep; 59(3):553-62. PubMed ID: 18953097
[TBL] [Abstract][Full Text] [Related]
9. Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK(2) receptors.
Kerr KP; Thai B; Coupar IM
Br J Pharmacol; 2000 Dec; 131(7):1461-7. PubMed ID: 11090121
[TBL] [Abstract][Full Text] [Related]
10. Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model.
Choppin A; Groke G; Bringas A; Stepan G; Dillon MP
Pharmacology; 2002 May; 65(2):96-102. PubMed ID: 11937780
[TBL] [Abstract][Full Text] [Related]
11. Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.
Mazzone SB; Geraghty DP
Br J Pharmacol; 2000 Mar; 129(6):1121-31. PubMed ID: 10725260
[TBL] [Abstract][Full Text] [Related]
12. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L
Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986
[TBL] [Abstract][Full Text] [Related]
13. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics.
Joos GF; Van Schoor J; Kips JC; Pauwels RA
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1781-4. PubMed ID: 8665034
[TBL] [Abstract][Full Text] [Related]
14. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
15. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice.
Teixeira RM; Santos AR; Ribeiro SJ; Calixto JB; Rae GA; De Lima TC
Eur J Pharmacol; 1996 Sep; 311(1):7-14. PubMed ID: 8884230
[TBL] [Abstract][Full Text] [Related]
16. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor.
Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Ferrer C; Giolitti A; Guelfi M; Rotondaro L; Warner FJ; Maggi CA
J Pharmacol Exp Ther; 1999 Aug; 290(2):487-95. PubMed ID: 10411554
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
Juszczak M
Neuro Endocrinol Lett; 2005 Aug; 26(4):367-72. PubMed ID: 16136007
[TBL] [Abstract][Full Text] [Related]
18. Plasma extravasation induced by neurokinins in conscious rats: receptor characterization with agonists and antagonists.
Nicolau M; Sirois MG; Bui M; Plante GE; Sirois P; Regoli D
Can J Physiol Pharmacol; 1993; 71(3-4):217-21. PubMed ID: 7691388
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of a 'septide-sensitive' inflammatory response in rat skin.
Ahluwalia A; Giuliani S; Maggi CA
Br J Pharmacol; 1995 Oct; 116(4):2170-4. PubMed ID: 8564245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
